Missouri Lawmakers Urged to Require Transparency in 340B Drug Program

JEFFERSON CITY, MISSOURI — Healthcare advocates are urging Missouri lawmakers to implement transparency requirements for the federal 340B Drug Pricing Program. They express concerns that large hospital systems may be capturing financial benefits while patients see little relief from prescription drug costs.

The 340B program allows eligible healthcare providers to purchase medications at substantial discounts, with the expectation that savings will be used to enhance access to care and provide discounted medications to low-income and underserved patients. However, current federal law does not require large hospital systems to disclose how these savings are utilized.

Lack of Accountability Raises Concerns

This absence of disclosure requirements has created an environment where financial gains can be achieved without providing clear evidence of patient benefit, according to healthcare policy experts. Evidence suggests the program has deviated from its original intent of helping vulnerable patients access affordable medications.

Recent analysis from Minnesota revealed that large hospital systems and for-profit entities often capture significant revenue through the 340B program, while patients experience minimal direct financial relief. Contract pharmacies, Third-Party Administrators (TPAs), and pharmacy benefit managers (PBMs) have also emerged as major beneficiaries, complicating the flow of funds.

Missouri Faces Similar Challenges

Without transparency requirements, questions about the program’s effectiveness in Missouri remain unanswered. Healthcare advocates want to know whether uninsured or underinsured patients are receiving discounted medications, if 340B savings are being reinvested into community health programs, and how much revenue is being generated by various entities.

The absence of clear answers undermines public trust and weakens the program’s credibility, potentially leaving patients without the benefits they were meant to receive under the federal initiative.

Reform Proposals on the Table

Healthcare policy experts emphasize that meaningful transparency does not mean dismantling the 340B program, but rather strengthening it to align with its original intent. They argue Missouri lawmakers have an opportunity to lead by implementing common-sense reforms.

The 340B Drug Pricing Program was established to assist safety-net providers in efficiently utilizing limited federal resources and expanding healthcare access for vulnerable populations. The program enables eligible healthcare providers to purchase medications at substantial discounts in exchange for using those savings to improve patient care.

Policymakers, patients, and taxpayers currently remain unaware of who is genuinely benefiting from the program due to the lack of mandatory reporting requirements. This opacity has transformed what advocates describe as a theoretical concern into a documented issue affecting healthcare access across multiple states.